Page last updated: 2024-11-02

pioglitazone and Colorectal Cancer

pioglitazone has been researched along with Colorectal Cancer in 9 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Research Excerpts

ExcerptRelevanceReference
" In the present study, we investigated the effect of pioglitazone on the development of azoxymethane-induced colon aberrant crypt foci (ACF) in KK-Ay obesity and diabetes model mice, and tried to clarify mechanisms by which the PPARγ ligand inhibits ACF development."7.78Suppressive effect of pioglitazone, a PPAR gamma ligand, on azoxymethane-induced colon aberrant crypt foci in KK-Ay mice. ( Fujii, G; Komiya, M; Mutoh, M; Nakano, K; Takahashi, M; Takasu, S; Teraoka, N; Ueno, T; Wakabayashi, K; Yamamoto, M; Yanaka, A, 2012)
"CAP, PGZ, and combination treatment nano-formulations were prepared by triblock (TB) (PCL-PEG-PCL) biodegradable copolymers to enhance drugs' bioavailability as anti-cancer agents."5.91Combination chemotherapy against colorectal cancer cells: Co-delivery of capecitabine and pioglitazone hydrochloride by polycaprolactone-polyethylene glycol carriers. ( Fathi-Azarbayjani, A; Kheradmand, F; Pouya, FD; Rasmi, Y; Salehi, R, 2023)
" In the present study, we investigated the effect of pioglitazone on the development of azoxymethane-induced colon aberrant crypt foci (ACF) in KK-Ay obesity and diabetes model mice, and tried to clarify mechanisms by which the PPARγ ligand inhibits ACF development."3.78Suppressive effect of pioglitazone, a PPAR gamma ligand, on azoxymethane-induced colon aberrant crypt foci in KK-Ay mice. ( Fujii, G; Komiya, M; Mutoh, M; Nakano, K; Takahashi, M; Takasu, S; Teraoka, N; Ueno, T; Wakabayashi, K; Yamamoto, M; Yanaka, A, 2012)
"Considering the role of PPARγ in colorectal cancer (CRC) as a tumor suppressor, the GEO database was used to identify candidate genes that affect the activation of PPARγ protein in CRC cell lines."2.82Identification of a novel interplaying loop of PPARγ and respective lncRNAs are involved in colorectal cancer progress. ( Esmaeili, M; Ghaedi, K; Hajipour, M; Hasehmi, M; Hushmandi, K; Mahdevar, M; Mirzaei, S; Mokhtari, K; Nasr-Esfahani, MH; Peymani, M, 2022)
"Although a correlation between pancreatic cancer and diabetes mellitus has long been suspected, the potential role diabetes mellitus plays in the pathogenicity of both hepatocellular carcinoma and colon cancer is becoming increasingly well defined."2.50Diabetes mellitus as a novel risk factor for gastrointestinal malignancies. ( Herrigel, DJ; Moss, RA, 2014)
"CAP, PGZ, and combination treatment nano-formulations were prepared by triblock (TB) (PCL-PEG-PCL) biodegradable copolymers to enhance drugs' bioavailability as anti-cancer agents."1.91Combination chemotherapy against colorectal cancer cells: Co-delivery of capecitabine and pioglitazone hydrochloride by polycaprolactone-polyethylene glycol carriers. ( Fathi-Azarbayjani, A; Kheradmand, F; Pouya, FD; Rasmi, Y; Salehi, R, 2023)
"Pioglitazone was chosen as agonist of PPAR-gamma and GW9662 used as a specific complete antagonist of PPAR-gamma."1.35[Role of peroxisome proliferators-activated receptor-gamma in the chemical prevention therapy of sulindac for precancerous lesions of rats]. ( Han, YJ; Jin, Z; Li, CF; Li, J; Lv, YM; Zhang, YP, 2009)

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (33.33)29.6817
2010's2 (22.22)24.3611
2020's4 (44.44)2.80

Authors

AuthorsStudies
Hajipour, M1
Mokhtari, K1
Mahdevar, M1
Esmaeili, M1
Peymani, M1
Nasr-Esfahani, MH1
Mirzaei, S1
Hasehmi, M1
Hushmandi, K1
Ghaedi, K1
Jia, X1
Qian, J1
Chen, H2
Liu, Q2
Hussain, S1
Jin, J2
Shi, J2
Hou, Y2
Xu, L1
Che, S1
Pouya, FD1
Salehi, R1
Rasmi, Y1
Kheradmand, F1
Fathi-Azarbayjani, A1
Herrigel, DJ1
Moss, RA1
Zhang, YP1
Lv, YM1
Li, J1
Han, YJ1
Jin, Z1
Li, CF1
Ueno, T1
Teraoka, N1
Takasu, S1
Nakano, K1
Takahashi, M1
Yamamoto, M1
Fujii, G1
Komiya, M1
Yanaka, A1
Wakabayashi, K1
Mutoh, M1
Lee, CJ1
Han, JS1
Seo, CY1
Park, TH1
Kwon, HC1
Jeong, JS1
Kim, IH1
Yun, J1
Bae, YS1
Kwak, JY1
Park, JI1
Richard, CL1
Blay, J1

Reviews

2 reviews available for pioglitazone and Colorectal Cancer

ArticleYear
Identification of a novel interplaying loop of PPARγ and respective lncRNAs are involved in colorectal cancer progress.
    International journal of biological macromolecules, 2022, Oct-31, Volume: 219

    Topics: Colonic Neoplasms; Colorectal Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Ligands; Pi

2022
Diabetes mellitus as a novel risk factor for gastrointestinal malignancies.
    Postgraduate medicine, 2014, Volume: 126, Issue:6

    Topics: Adenocarcinoma; Carcinoma, Hepatocellular; Colorectal Neoplasms; Diabetes Complications; Humans; Hyp

2014

Other Studies

7 other studies available for pioglitazone and Colorectal Cancer

ArticleYear
PPARγ agonist pioglitazone enhances colorectal cancer immunotherapy by inducing PD-L1 autophagic degradation.
    European journal of pharmacology, 2023, Jul-05, Volume: 950

    Topics: B7-H1 Antigen; CD8-Positive T-Lymphocytes; Colorectal Neoplasms; Humans; Immunotherapy; Pioglitazone

2023
PPARγ agonist inhibits c-Myc-mediated colorectal cancer tumor immune escape.
    Journal of cellular biochemistry, 2023, Volume: 124, Issue:8

    Topics: Colorectal Neoplasms; Gene Expression Regulation; Humans; Pioglitazone; PPAR gamma; Proto-Oncogene P

2023
Combination chemotherapy against colorectal cancer cells: Co-delivery of capecitabine and pioglitazone hydrochloride by polycaprolactone-polyethylene glycol carriers.
    Life sciences, 2023, Nov-01, Volume: 332

    Topics: Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Drug Therapy, Combination; Human Umbilica

2023
[Role of peroxisome proliferators-activated receptor-gamma in the chemical prevention therapy of sulindac for precancerous lesions of rats].
    Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2009, Apr-18, Volume: 41, Issue:2

    Topics: 1,2-Dimethylhydrazine; Anilides; Animals; Colorectal Neoplasms; Male; Pioglitazone; PPAR gamma; Prec

2009
Suppressive effect of pioglitazone, a PPAR gamma ligand, on azoxymethane-induced colon aberrant crypt foci in KK-Ay mice.
    Asian Pacific journal of cancer prevention : APJCP, 2012, Volume: 13, Issue:8

    Topics: Aberrant Crypt Foci; Adipokines; Animals; Azoxymethane; Biomarkers; Carcinogens; Colorectal Neoplasm

2012
Pioglitazone, a synthetic ligand for PPARgamma, induces apoptosis in RB-deficient human colorectal cancer cells.
    Apoptosis : an international journal on programmed cell death, 2006, Volume: 11, Issue:3

    Topics: Apoptosis; Caspases; Cell Cycle Proteins; Cell Line, Tumor; Colorectal Neoplasms; Cyclooxygenase 2;

2006
Thiazolidinedione drugs down-regulate CXCR4 expression on human colorectal cancer cells in a peroxisome proliferator activated receptor gamma-dependent manner.
    International journal of oncology, 2007, Volume: 30, Issue:5

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Membrane; Colorectal Neoplasms; Dose-Response Relation

2007